RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Recommendation |
|
Starting dose
|
30–60 mg orally every 4–6 hours as required |
|
Titration
|
Not applicable; dose adjusted based on symptom relief |
|
Usual maintenance dose
|
60 mg every 6 hours |
|
Maximum dose
|
240 mg/day |
|
Duration
|
Short-term use only (≤5–7 days recommended) |
| Parameter | Recommendation |
|
Starting dose
|
60 mg orally three times daily |
|
Titration
|
Not applicable |
|
Usual maintenance dose
|
60 mg three times daily |
|
Maximum dose
|
180 mg/day |
|
Duration
|
As assessed by urogynecology specialist |
| Age Group | Starting Dose | Frequency | Maximum Daily Dose | Maximum Duration |
| 6–12 years | 30 mg orally | Every 6 hours | 120 mg/day | ≤5–7 days |
| 2–5 years | 15 mg orally | Every 6 hours | 60 mg/day | ≤5 days |
| Renal Function | Recommendation |
| eGFR ≥30 mL/min/1.73m² | No dose adjustment required |
| eGFR <30 mL/min/1.73m² | Use with caution; extend dosing interval to every 8–12 hours |
| Haemodialysis | Limited data available; potential for accumulation — avoid unless necessary |
| Severity | Recommendation |
| Mild impairment | No dose adjustment required; monitor for adverse effects |
| Moderate impairment | No dose adjustment required; monitor for CNS side effects |
| Severe impairment | Use with caution; CNS adverse effects may be increased |
| Consideration | Recommendation |
| Overall safety | Use with caution; limited safety data in Indian obstetric sources |
| Risk | Avoid during first trimester — possible association with abdominal wall defects (gastroschisis) based on limited international data |
| When it may be used | Only if benefits clearly outweigh risks; avoid prolonged use |
| Preferred alternatives | Antihistamines like chlorpheniramine (in second trimester onwards) if symptomatic relief required |
| Monitoring | Maternal blood pressure; fetal growth if repeated use necessary |
| Consideration | Recommendation |
| Compatibility | Compatible with breastfeeding in short-term, occasional use |
| Drug levels in milk | Low |
| Preferred alternatives | Short-acting antihistamines (e.g., loratadine) if available |
| Infant monitoring | Irritability, sleep disturbances, poor feeding |
| Consideration | Recommendation |
| Starting dose | 30 mg every 6–8 hours (lower end of dose range) |
| Titration | Slower titration preferred |
| Risks | Confusion, insomnia, urinary retention, blood pressure elevation, tachycardia |
| Monitoring | Blood pressure, heart rate, urinary symptoms, CNS effects |
| Interacting Drug | Effect / Mechanism | Recommendation |
| Monoamine oxidase inhibitors (MAOIs) | Risk of hypertensive crisis due to potentiation of sympathomimetic effects |
Contraindicated — avoid within 14 days of MAOI use
|
| Linezolid | MAOI activity; risk of serotonin syndrome and hypertensive crisis |
Avoid combination
|
| Tricyclic antidepressants (e.g., amitriptyline) | Potentiation of vasopressor effect |
Avoid or monitor closely
|
| Digoxin | Potential to aggravate arrhythmias |
Use with caution; monitor cardiac rhythm
|
| Interacting Drug | Effect / Mechanism | Recommendation |
| Beta-blockers | May reduce antihypertensive efficacy, especially non-selective agents | Monitor blood pressure |
| Antihypertensives (esp. alpha-blockers) | Risk of blood pressure elevation | Monitor blood pressure closely |
| SSRIs/Serotonergic drugs | Rarely associated with additive CNS stimulation | Monitor for toxicity |
| Caffeine | Additive stimulation effects | Advise limiting caffeine intake |
| Sympathomimetics (other decongestants) | Additive cardiovascular effects | Avoid concurrent use |
| Adverse Effect | Clinical Note |
| Hypertensive crisis | Especially with MAOIs or overdose; requires immediate discontinuation and emergency management |
| Arrhythmias | Rare; more likely in patients with pre-existing heart disease |
| Seizures | Rare; especially in overdose or young children |
| Psychosis-like symptoms | May occur with high doses or prolonged use |
| Acute urinary retention | Especially in older males with prostatic hypertrophy |
| Phase | Parameters |
|
Baseline
|
Blood pressure, heart rate in patients with cardiovascular risk factors |
|
After initiation
|
Monitor for insomnia, palpitations, blood pressure changes |
|
Long-term
|
Not recommended for chronic use (>7 days); reassess need and consider alternative management |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.